AKT1 and hepatocellular carcinoma: Currently, Yang et al. (2024) elaborated on the in vitro therapeutic potential of EGCG in HCC and found that EGCG modulated PIK3CA expression, inhibited PI3K/AKT, and reduced proliferation in HepG2 cells.